Hot Deals:
5 star business 505.00 (1.00 %) a v thomas 12,800.00 (-1.54 %) aether industries 642.00 amol minechem 620.00 (1.64 %) anglo french 720.00 (-5.26 %) apl metals 44.00 (-2.22 %) aricent 595.00 (-0.83 %) arohan 197.00 (-3.90 %) assam carbon 243.00 (-2.80 %) atlas copco 4,900.00 (6.52 %) auckland 135.00 (-3.57 %) axles 135.00 (-3.57 %) b9 bira 830.00 (-1.19 %) balmer lawrie van leer 300.00 bharat hotels 160.00 (-1.23 %) bikaji foods 340.00 (4.62 %) boat 1,175.00 (-2.08 %) c & s electric 400.00 capgemini 12,000.00 (-4.00 %) care health 145.00 (-3.33 %) carrier aircon 261.00 (-3.33 %) cial 185.00 (-0.54 %) csfbl 300.00 (-0.99 %) csk 178.00 (1.71 %) dalmia bharat refractories 95.00 (-4.04 %) delhivery 504.00 (-1.75 %) east india pharmaceutical 43.00 (2.38 %) eaton fluid 281.00 (0.36 %) electronica plastic 4,300.00 (2.38 %) elgi ultra 400.00 elofic 1,909.00 (0.47 %) epiroc 1,224.00 (-2.08 %) esl steel 47.00 (4.44 %) fincare 69.50 (-0.71 %) fino paytech 170.00 (-2.86 %) frick india 4,300.00 (-2.27 %) gkn drive 1,150.00 (-0.95 %) godavari biorefineries 71.00 (1.43 %) hdbfsl 656.00 (-2.09 %) hdfc ergo 363.80 hdfc securities 14,000.00 (-2.78 %) hella india 155.00 (3.33 %) hero fincorp 800.00 (-5.88 %) hicks 2,100.00 (-2.55 %) hira ferro 140.00 (-6.67 %) honeywell electrical 4,240.00 (-0.24 %) icex 6.00 (-13.04 %) incred financial 100.00 india carbon 1,300.00 (1.56 %) india exposition mart 132.00 (-2.22 %) indian potash limited 1,405.00 (0.36 %) indofil industries 710.00 (-3.40 %) infinite computer 700.00 inkel 12.95 (-0.38 %) ixigo 128.00 (-1.54 %) jana sfbl 75.00 kial 120.00 (-2.44 %) klm axiva 10.00 kurlon enterprise 660.00 (-1.49 %) kurlon limited 460.00 (-4.17 %) lava 155.00 (-3.13 %) manipal hfsl 72.50 (0.69 %) manjushree technopack 1,150.00 (-3.36 %) martin and harris 2,200.00 (-4.35 %) merino 3,050.00 (-1.61 %) minosha 320.00 (-1.54 %) mitsubishi heavy industries 355.00 (1.43 %) mkcl 415.00 (1.22 %) mobikwik 600.00 (-4.00 %) mohan meakin 1,250.00 (-3.85 %) mohfl 12.00 (1.69 %) msei 1.19 (-0.83 %) msil 54.00 (-1.82 %) nayara energy 165.00 (1.23 %) ncdex 275.00 ncl buildtek 250.00 (-6.02 %) ncl holdings 50.00 (-5.66 %) nse 3,411.00 (-0.26 %) orbis financial 72.00 (2.86 %) oswal minerals 42.50 (1.19 %) otis 4,000.00 (-2.44 %) oyo rooms 135.00 (0.75 %) panasonic appliances 306.00 (0.33 %) panasonic avc 29.10 (0.34 %) paymate india 700.00 pharm easy 59.00 (-1.67 %) philips domestic 603.00 (0.50 %) philips india 1,150.00 (-2.21 %) pnb metlife 70.00 ramaraju surgical 525.00 (-4.55 %) reliance general insurance 340.00 resins plastics 406.00 (0.25 %) ring plus 350.00 (-3.05 %) rrl 3,000.00 (-1.64 %) sabmiller 405.00 (-11.96 %) satya micro 200.00 scottish assam 654.00 (0.62 %) shriram life 251.00 (0.40 %) signify 1,126.00 (0.09 %) smile microfin 80.00 (-2.44 %) sri vishnu shankar 640.00 (-1.54 %) sterlite power 970.00 (2.11 %) studds 1,350.00 (-0.74 %) t stanes 675.00 tata tech 5,300.00 (-1.85 %) tmbl 515.00 (3.00 %) trl krosaki 1,390.00 (-0.71 %) utkarsh coreinvest 166.00 (0.61 %) vikram solar 51.00 (2.00 %) xerox 230.00 (1.77 %)
×

arch pharma labs Limited

50.00
+ 0.00 %
Scrip Name
ARCH PHARMA
ISIN No.
INE182F01017
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,076
Market Capitalization
759.62 Crore

ARCH PHARMALABS LIMITED UNLISTED SHARE


ABOUT ARCH PHARMA LABS LIMITED


ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.


The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.


The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.


Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.



INCORPORATION DETAILS


CIN

U24231MH1993PLC150891

Registration Date

02 April 1993

Category/Sub-category of the Company

Company Limited by Shares

Address of the Registered office and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Name, Address and Contact Details of

Registrar and Transfer Agent, if any

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

 

PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

 

BOARD OF DIRECTORS

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)


PARTICULARS OF SUBSIDIARY AND ASSOCIATE COMPANIES

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%


SHAREHOLDING PATTERN

(As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%


INDUSTRY OUTLOOK

 

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.


In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.


Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.


PROFIT & LOSS STATEMENT OF ARCH PHARMA LABS LIMITED(In Rs. Crores)

 

Particulars

FY 2020

FY 2019

FY 2018

Revenue from Operations

632.29

476.58

247.19

EBITDA

38.43

14.05

-263.02

Finance Cost

204.67

162.84

82.52

Depreciation

30.30

32.54

39.10

Other Income

19.22

38.20

0.25

Profit Before Tax and Exceptional items

-177.32

-143.12

-384.39

Exceptional items

17.13

12.14

323.25

Total Tax

-0.69

0.34

0.00

Profit After Tax (PAT)

-159.50

-131.31

-61.14

EPS

-10.5

-8.64

-8.92

 

BALANCE SHEET OF ARCH PHARMA LABS LIMITED (In Rs. Crores)


PARTICULARS

2020

2019

ASSETS



NON-CURRENT ASSETS



Tangible assets

998.36

1052.33

Intangible assets

5.18

9.17

Goodwill ( On Consolidation)

9.71

9.71

Financial assets

207.11

207.33

TOTAL NON-CURRENT ASSETS

1,220.36

1,278.55

CURRENT ASSETS



Inventories

832.58

729.71

Trade receivables

439.39

589.61

Cash and Cash Equivalents

2.77

4.19

Short-term loans and advances

614.29

628.74

TOTAL CURRENT ASSETS

1,889.02

1,952.25

TOTAL ASSETS

3,109.38

3,230.80

EQUITY AND LIABILITIES



Share Capital

151.92

151.92

Share Application Money

17.51

17.51

Surplus

-1,776.35

-1,582.75

Minority Interest

3.39

3.39

TOTAL EQUITY

-1,603.52

-1,409.92

NON-CURRENT LIABILITIES



Long-term borrowings

3,070.84

3,451.14

TOTAL NON-CURRENT LIABILITIES

3,070.84

3,451.14

CURRENT LIABILITIES



Short-term borrowings

113.12

113.22

Trade payables

475.48

550.94

Other current liabilities

1,048.25

520.22

Short-term provisions

5.21

5.21

TOTAL CURRENT LIABILITIES

1,642.06

1,189.58

TOTAL LIABILITIES

4,712.90

4,640.72

TOTAL EQUITY AND LIABILITIES

3,109.38

3,230.80

 

DIVIDEND HISTORY

Particulars

2020

2019

2018

Dividend (final + interim) (In Rs.)

Nil

Nil

Nil

 

PERFORMANCE OF THE COMPANY

The revenue from operations of the company increased by 32.67% from Rs. 486.58 Crore in FY 2019 to Rs. 632.29 Crore in FY 2020. The increase in revenue can mainly be attributed to the increase in operational activities at the manufacturing sites and is expected to continue in the coming few years.


EBITDA of the company has increased by 173% from Rs. 14.05 Crore in FY 2019 to Rs. 38.43 Crore in FY 2020. EBITDA margins have improved from 2.95% in FY 2019 to 6.08% in FY 2020.


The finance cost of the company increased by 25.68% from Rs. 162.84 Crore in FY 2019 to Rs. 204.67 Crore in FY 2020.


The company has incurred a loss of Rs. 131.31 Crore in FY 2019, which increased to a loss of Rs. 159.50 Crore in FY 2020. These losses are mainly because of the increasing financial cost of the company.


The current Ratio of the company as of 31st March 2020 was 1.15.


The Company has not given any dividend for the past three years.

Powered by Froala Editor

Wealth Wisdom - WWIPL
Support Megha Support Neha Support Pallavi